Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

ULURU Inc. · with United States Department of Defense · NCT05496296

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–85 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
300
US sites recruiting
13
Study start
April 30, 2023
Record last updated
November 20, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® in patients with stage 2, stage 3 and stage 4 pressure injury wounds. Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Subjects can be enrolled in the study either as an outpatient, or while hospitalized. Half of the subjects will be randomized to standard of care treatment, and the other half will be randomized to Altrazeal®. There are a total of up to 12 study visits taking place over 12 weeks.

Being studied: Altrazeal® Transforming Powder Dressing

Conditions: Pressure Ulcers Stage II; Pressure Ulcers Stage III; Pressure Ulcer, Stage IV

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 to 85 years of age;
  • Stage 2, 3, or 4 Pressure Injuries;
  • Wound exudate is mild to moderate;
  • No clinically active wound infection (clinical diagnosis);
  • Able and willing to provide written (not proxy) informed consent;
  • Clinically stable, as determined by assessment of medical history, vital signs, physical examination, and laboratory testing prior to enrollment.

Exclusion Criteria

  • Known allergy or hypersensitivity to TPD or its components;
  • Pressure injuries classified as unstageable, deep tissue pressure injury, or Stage 1;
  • Heavily exudative wounds;
  • Wound infection as defined as the presence of a least two of the following: local swelling or in duration, erythema >0.5cm around the ulcer in any direction, local tenderness or pain local warmth and purulent discharge;
  • Poorly controlled diabetes with HgbA1C >12 (as documented in the last 3 months);
  • Body Mass Index (BMI) >45 kg/m2;
  • Venous stasis disease or lymphedema in the affected limb (if wound is located on the limb);
  • Moderate to severe chronic limb ischemia Ankle Brachial Index (ABI) \<0.7 on the affected limb, if wound is located on the limb);
  • Received immunosuppression or biologics in the last six weeks and/or is expected to receive either at any point during the study;
  • Selected concurrent treatments (e.g., hyperbaric oxygen, topical oxygen therapy, electrical stimulation, ultrasound, cellular or acellular skin substitutes) during study period that may impact study outcomes;
  • Wounds with necrosis unable to undergo prior definitive debridement;
  • Fistulas;
  • Active gangrene;
  • Untreated HIV;
  • Currently pregnant or lactating;
  • Impending organ transplant;
  • Vulnerable populations including prisoners, pediatrics, cognitively impaired, unconscious, and illiterate patients;
  • Unwilling or unable to comply with offloading recommendations;
  • If, in the opinion of the clinical investigator, a subject is a poor candidate for this study because:
  • Unable to keep research appointments;
  • Poorly controlled incontinence which may impact study outcomes (e.g., depending on the location of the wound);
  • Participated in another investigative study within 3 months of enrollment that could interfere with study outcomes;
  • Active alcohol or substance abuse (cocaine, heroin, or other substances) that may interfere with healing or subject compliance with visit schedules;
  • Concurrent clinical condition(s) that could pose a health risk to patient or influence outcome of study;
  • Not suitable for study participation. -

Recruiting US locations

  • San Diego VA

    San Diego, CA 92161

    Site contact: Henry York, MD · 858-552-8585 · Henry.York@va.gov

  • Medstar Georgetown University Hospital

    Washington D.C., DC 20007

    Site contact: Deanna Curbeam · 202 444 8751 · Deanna.Curbeam@medstar.net

  • MedStar National Rehabilitation Hospital

    Washington D.C., DC 20010

    Site contact: Suzanne L Groah, MD · (202) 877-1000 · Suzanne.L.Groah@medstar.net

  • Medstar Franklin Square Medical Center

    Baltimore, MD 21237

    Site contact: Paul Carroll, DPM · (443) 777-7000 · paul.j.carroll@medstar.net

  • Medstar Good Samaritan Hospital

    Baltimore, MD 21239

    Site contact: Lumanti Manandhar · (443) 444-8000 · lumanti.Manandhar@medstar.net

  • Rutgers New Jersey Medical School, Ambulatory Care Center-Wound Care Clinic

    Newark, NJ 07103

    Site contact: Mark Granick, MD · 973-972-1129 · mgranickmd@njms.rutgers.edu

  • Northwell Health System/Zucker School of Medicine

    Lake Success, NY 11042

    Site contact: Sally Kaplan, RN · 516-233-3781 · skaplan2@northwell.edu

  • NYU Langone Hospital-Long Island

    Mineola, NY 11501

    Site contact: Scott Gorenstein, MD · 516-663-8498 · Scott.gorenstein@nyulangone.org

  • James J. Peters VA Medical Center

    The Bronx, NY 10468

    Site contact: Galea Marinella, MD · 718-584-9000 · Marinella.Galea@va.gov

  • Westchester Medical Center, 100 Woods, Road, Taylor Care Pavillion

    Valhalla, NY 10595

    Site contact: Carlo Gwardschaladse, PA · 914-493-3047 · Carlo.Gwardschaladse@wmchelath.org

  • University of Pittsburgh Medical Center (UPMC) Presbyterian

    Pittsburgh, PA 15213

    Site contact: Cecilia Zamarripa, PhD, RN, CWON · 412-647-7728 · zamarripaca@upmc.edu

  • VA North Texas Healthcare System

    Dallas, TX 75243

    Site contact: David Truong, DPM · 214-857-2602 · David.Truong1@va.gov

  • Michael E. DeBakey Houston VAMC

    Houston, TX 77030

    Site contact: Aimee Garcia, MD · 512-387-1876 · Aimee.Garcia@va.gov

Study contacts (from the official record)

  • Kerry Wallace · 513 702 7536 · kwallace@altrazeal.com
  • Susan St. John, MSN · sstjohn@altrazeal.com
Comparison of Transforming Powder Dressing to NPIAP Recommended… (NCT05496296) | Bored Studies